The U.S. FDA has approved AstraZeneca PLC (AZN) and Daiichi Sankyo's (TYO: 4568) fam-trastuzumab deruxtecan (Enhertu) in combination with pertuzumab for first-line treatment of HER2-positive breast cancer. This decision follows the DESTINY-Breast09 trial, which demonstrated a median progression-free survival (PFS) of 40.7 months for the Enhertu regimen, significantly outperforming the standard THP regimen's 26.9 months. Pertuzumab is marketed by Roche (SWX: ROG).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.